Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O60907
UPID:
TBL1X_HUMAN
Alternative names:
SMAP55; Transducin beta-like protein 1X; Transducin-beta-like protein 1, X-linked
Alternative UPACC:
O60907; A8K044; A8K4J7; Q86UY2
Background:
The F-box-like/WD repeat-containing protein TBL1X, also known as SMAP55 and Transducin beta-like protein 1X, plays a pivotal role in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units. It is integral to transcription activation mediated by nuclear receptors, facilitating the proteasomal degradation of transcription repressor complexes.
Therapeutic significance:
TBL1X's involvement in Hypothyroidism, congenital, non-goitrous, 8, a form of central hypothyroidism characterized by sub-optimal thyroid hormone secretion, highlights its potential as a target for therapeutic intervention. Understanding the role of TBL1X could open doors to potential therapeutic strategies.